| Similar Articles |
|---|
 |
The Motley Fool
April 9, 2008
Brian Orelli |
Repligen Gets a Surprise Infusion of Cash Bristol-Myers Squibb agrees to pay Repligen royalties in their patent-infringement lawsuit.   |
The Motley Fool
December 10, 2007
Brian Lawler |
ImClone in a Giving Mood ImClone Systems and partner Sanofi-Aventis each decide to shell out $60 million to settle a lawsuit over the patents on cancer therapy Erbitux. |
The Motley Fool
August 30, 2007
Brian Lawler |
ImClone's Healthy Pipeline With three new molecules in phase 2 testing and another two in phase 1 testing by the end of the year, ImClone may not be completely reliant on Erbitux for its fortunes in the coming years. |
The Motley Fool
April 17, 2007
Brian Lawler |
ImClone Loses an Indication ImClone's lead drug fails in a clinical trial. Investors, take note. |
The Motley Fool
July 20, 2006
Brian Lawler |
No Surprises From ImClone ImClone's lead product experienced strong revenue growth in the second quarter. But biotech investing is fraught with risk. Investors, take note. |
The Motley Fool
August 1, 2008
Brian Lawler |
Is $60 a Share Enough for ImClone? Bristol-Myers Squibb announced a $60-per-share offer for ImClone Systems, but are shareholders going to go for the deal? |
The Motley Fool
October 7, 2008
Brian Orelli |
Eli Lilly's Risky Gamble Eli Lilly is desperate, and the high acquisition price of ImClone shows it. |
The Motley Fool
October 2, 2008
Brian Orelli |
Will Lilly Buy ImClone's Troubles? Eli Lilly is reportedly ImClone's mystery suitor. Would it be a good deal? |
The Motley Fool
January 29, 2007
Brian Lawler |
ImClone Fights The Competition The drug developer's performance has been alright, but the competition is heating up. Investors, take note. |
The Motley Fool
September 11, 2008
Brian Lawler |
ImClone and Bristol-Myers' Unfinished Business ImClone rejects Bristol's offer, but likely isn't done dealing with it yet. |
The Motley Fool
April 27, 2007
Brian Lawler |
Tracking ImClone The biopharmaceutical releases first-quarter financial results. Investors, take note. |
The Motley Fool
April 28, 2008
Brian Lawler |
ImClone on the Upswing The pharmaceutical's latest results show continuing improvement. |
The Motley Fool
October 30, 2007
Brian Lawler |
ImClone Onward Global sales, and excitement about new label expansions for lead drug Erbitux, lift ImClone's third-quarter financial results. |
The Motley Fool
June 12, 2007
Brian Lawler |
ImClone Tries To Improve Erbitux ImClone is running trials to see if the drug can be used in earlier stages of cancer. Investors shouldn't discount the importance of an approved drug's product label. |
BusinessWeek
March 8, 2004
Arnst & Ewing |
The Odyssey Of A Cancer Drug How ImClone overcame scandal and FDA objections to get Erbitux to market |
The Motley Fool
April 5, 2007
Brian Lawler |
ImClone Steps to the Front ImClone announces a successful clinical trial for the cancer drug Erbitux. Investors, take note. |
The Motley Fool
April 20, 2004
Charly Travers |
Great Googly Moogly, ImClone The biopharmaceutical company's stock is going crazy again. |
The Motley Fool
September 13, 2007
Brian Lawler |
ImClone Expanding on Erbitux ImClone's turnaround continues with positive results in a cancer study with their lead drug Erbitux. |
Fast Company
December 2005 |
Brilliant Biotech Our Innovation Scorecard takes a look at biotechnology, one of the hottest industries around, and comes up with four companies to watch. |
The Motley Fool
August 1, 2007
Brian Lawler |
ImClone Inches Along ImClone reports slower than expected sales growth with its lead cancer fighting drug, Erbitux. ImClone needs to expand the use of Erbitux into new markets to return to a period of sustained top-line growth. |
The Motley Fool
April 27, 2004
Alyce Lomax |
Imagining ImClone It's been hard to ignore the lure of cancer drugs over the last several days. Today, ImClone shares leapt after the company reported stellar first-quarter profits, boosted by its launch of colon cancer drug Erbitux. |
The Motley Fool
July 16, 2007
Brian Lawler |
Slight Setback for ImClone ImClone announces a failed cancer study. Investors, take note. |
The Motley Fool
September 22, 2008
Brian Lawler |
Why Bristol-Myers Won't Pull Its ImClone Bid Bristol-Myers might drop its cash bid of $60 per share to acquire longtime partner ImClone Systems. |
The Motley Fool
February 12, 2004
Bill Mann |
ImClone's Mysterious Plunge Investors flee the stock the instant before it receives great news. Oops. |
The Motley Fool
September 21, 2006
Brian Lawler |
ImClone's Board Shakeup A new face in the boardroom heralds change for the troubled company. Shareholders yesterday elected notorious corporate raider Carl Icahn to the company's board of directors. |
The Motley Fool
June 4, 2008
Brian Lawler |
Erbitux's Deceptively Disappointing Results Poorly received lead-drug data batters ImClone shares. |
The Motley Fool
September 29, 2006
Brian Lawler |
ImClone Under Siege Board member Carl Icahn moves to take control, and it appears as though shareholders agree. |
The Motley Fool
September 1, 2004
Bill Mann |
Triumph of Hope Over Reason A frighteningly expensive drug of marginal efficacy begets triple-digit multiples? Bring on the miracles. Standard & Poor's reiterated its "buy" rating of ImClone. |
The Motley Fool
October 18, 2004
Charly Travers |
Biotech's 5-Baggers How can yesterday's biotech winners lead you to today's top performers? |
| Knowledge@Wharton |
The Benefits Are Mutual in New Wave of Biotech/Pharma Alliances The spat that erupted between pharma giant Bristol-Myers Squibb and biotech firm ImClone Systems over their partnership to develop a new cancer drug put the structure of alliances between discovery research firms and big drug makers under a microscope... |
The Motley Fool
August 5, 2008
Brian Lawler |
An ImClone Deal Will Get Done Despite his tough talk, Icahn will likely complete a buyout of ImClone. |
The Motley Fool
August 22, 2006
Brian Gorman |
NICE Unkind to Biotech Developments in the U.K.'s drug coverage may hurt U.S. biotechs. Biotech investors, keep your eyes on this issue. |
The Motley Fool
February 16, 2007
Brian Lawler |
The Biotech Academy Awards Investors, here are some biotech Oscars for last year's performances: The Biotech Best Picture award -- Celgene... The Biotech Best Drama -- Elan and BiogenIdec... etc. |
Fast Company
September 2004
Linda Tischler |
The Trials of ImClone A founder in handcuffs, financials in disarray, and a vital product in doubt-for CEO Daniel Lynch, it was the turnaround from hell. |
The Motley Fool
December 31, 2007
Brian Lawler |
The Biotech Year in Review Following the biotech sector is never dull, and 2007 was no exception to the rule. Let's take a look at the highlights and lowlights of 2007. |
The Motley Fool
October 4, 2006
Brian Lawler |
Unwelcome Guests at ImClone ImClone's board of directors votes against Carl Icahn's proposed removal of six company directors. Short-term shareholders that are able to cash out with Icahn, will possibly have a nice gain to take home. |
Fast Company
December 2005
Keith H. Hammonds |
A Bear Market for Courage A retrospective look at courageous businesses noted in 2004. |
